[Neurotropin suppression of the manifestations of the naloxone-provoked withdrawal syndrome in morphine-dependent rats].
Neurotropin was developed by Nippon Zoki Pharmaceutical Co. Ltd. It is produced by inoculating vaccine virus into rabbits and the effective substances are extracted from neuro-immuno inflamed cutaneous tissue. In the present study it was found that intraperitoneally administered neurotropin potently inhibits naloxone-precipitated withdrawal syndrome in morphine-dependent rats. Also we get the experimental evidence that neurotropin increases morphine action but has no positive-reinforcing properties. These data indicate the possibility of testing neurotropin as a medicine for treating opiate-abused patients.
Sudakov
S K
SK
Konstantinopol'skiĭ
M A
MA
Surkova
L A
LA
Tiurina
I V
IV
Konishi
J
J
Yumia
H
H
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D002389:Catatonia / Q000139:chemically induced / Q000188:drug therapy; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D008297:Male; D009020:Morphine / Q000009:adverse effects*; D009021:Morphine Dependence / Q000188:drug therapy*; D009270:Naloxone / Q000037:antagonists & inhibitors*; D011134:Polysaccharides / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000209:etiology
D000276:Adjuvants, Immunologic; D011134:Polysaccharides; D009270:Naloxone; C010491:neurotropin; D009020:Morphine
Podavlenie neĭrotropinom proiavleniĭ provotsirovannogo naloksonom sindroma otmeny u morfinzavisimykh krys.